This is interesting - UNTIL I tried validating the author's statement regarding the CDC not having a virus sample:
From Author:
"CDC itself admits to having no identifiable virus
Deeply hidden in an official document on Covid-19, the CDC ruefully admitted as early as summer 2020 that it does not have a measurable virus: ‘As no quantified (= measured) isolated virus objects of 2019-nCoV are available at this time…’ (page 39 of the ‘CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel’ (July 13) In other words, the CDC, as one of THE leading medical authorities in the world, could not, and still cannot, demonstrate a virus."
Quality Control
• Quality control requirements must be performed in conformance with local, state, and federal
regulations or accreditation requirements and the user’s laboratory’s standard quality control
procedures. For further guidance on appropriate quality control practices, refer to 42 CFR
493.1256.
• Quality control procedures are intended to monitor reagent and assay performance.
• Test all positive controls prior to running diagnostic samples with each new kit lot to ensure all
reagents and kit components are working properly.
• Good laboratory practice (cGLP) recommends including a positive extraction control in each
nucleic acid isolation batch.
• Although HSC is not included with the 2019-nCov rRT-PCR Diagnostic Panel, the HSC extraction
control must proceed through nucleic acid isolation per batch of specimens to be tested.
• Always include a negative template control (NTC) and the appropriate positive control (nCoVPC)
in each amplification and detection run. All clinical samples should be tested for human RNase P
gene to control for specimen quality and extraction.
Limitations
• All users, analysts, and any person reporting diagnostic results should be trained to perform this
procedure by a competent instructor. They should demonstrate their ability to perform the test
and interpret the results prior to performing the assay independently.
• Performance of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been established
in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs,
sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal
wash/aspirate or nasal aspirate).
• Negative results do not preclude 2019-nCoV infection and should not be used as the sole basis
for treatment or other patient management decisions. Optimum specimen types and timing for
peak viral levels during infections caused by 2019-nCoV have not been determined. Collection of
multiple specimens (types and time points) from the same patient may be necessary to detect
the virus.
• A false-negative result may occur if a specimen is improperly collected, transported or handled.
False-negative results may also occur if amplification inhibitors are present in the specimen or if
inadequate numbers of organisms are present in the specimen.
• Positive and negative predictive values are highly dependent on prevalence. False-negative test
results are more likely when prevalence of disease is high. False-positive test results are more
likely when prevalence is moderate to low.
• Do not use any reagent past the expiration date.
• If the virus mutates in the rRT-PCR target region, 2019-nCoV may not be detected or may be
detected less predictably. Inhibitors or other types of interference may produce a false-negative
result. An interference study evaluating the effect of common cold medications was not
performed.
• Test performance can be affected because the epidemiology and clinical spectrum of infection
caused by 2019-nCoV is not fully known. For example, clinicians and laboratories may not know
39
CDC-006-00019, Revision: 06 CDC/DDID/NCIRD/ Division of Viral Diseases Effective: 12/01/2020
In summary - author hyperlinks to a study, quotes it, tells us where the quote is to be found, AND there is no such quote.
This is interesting - UNTIL I tried validating the author's statement regarding the CDC not having a virus sample:
From Author:
"CDC itself admits to having no identifiable virus Deeply hidden in an official document on Covid-19, the CDC ruefully admitted as early as summer 2020 that it does not have a measurable virus: ‘As no quantified (= measured) isolated virus objects of 2019-nCoV are available at this time…’ (page 39 of the ‘CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel’ (July 13) In other words, the CDC, as one of THE leading medical authorities in the world, could not, and still cannot, demonstrate a virus."
Author hyperlinks to FDA document. https://www.fda.gov/media/134922/download Here is page 39 in full for your own checking:
Quality Control • Quality control requirements must be performed in conformance with local, state, and federal regulations or accreditation requirements and the user’s laboratory’s standard quality control procedures. For further guidance on appropriate quality control practices, refer to 42 CFR 493.1256. • Quality control procedures are intended to monitor reagent and assay performance. • Test all positive controls prior to running diagnostic samples with each new kit lot to ensure all reagents and kit components are working properly. • Good laboratory practice (cGLP) recommends including a positive extraction control in each nucleic acid isolation batch. • Although HSC is not included with the 2019-nCov rRT-PCR Diagnostic Panel, the HSC extraction control must proceed through nucleic acid isolation per batch of specimens to be tested. • Always include a negative template control (NTC) and the appropriate positive control (nCoVPC) in each amplification and detection run. All clinical samples should be tested for human RNase P gene to control for specimen quality and extraction. Limitations • All users, analysts, and any person reporting diagnostic results should be trained to perform this procedure by a competent instructor. They should demonstrate their ability to perform the test and interpret the results prior to performing the assay independently. • Performance of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been established in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate). • Negative results do not preclude 2019-nCoV infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by 2019-nCoV have not been determined. Collection of multiple specimens (types and time points) from the same patient may be necessary to detect the virus. • A false-negative result may occur if a specimen is improperly collected, transported or handled. False-negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen. • Positive and negative predictive values are highly dependent on prevalence. False-negative test results are more likely when prevalence of disease is high. False-positive test results are more likely when prevalence is moderate to low. • Do not use any reagent past the expiration date. • If the virus mutates in the rRT-PCR target region, 2019-nCoV may not be detected or may be detected less predictably. Inhibitors or other types of interference may produce a false-negative result. An interference study evaluating the effect of common cold medications was not performed. • Test performance can be affected because the epidemiology and clinical spectrum of infection caused by 2019-nCoV is not fully known. For example, clinicians and laboratories may not know 39 CDC-006-00019, Revision: 06 CDC/DDID/NCIRD/ Division of Viral Diseases Effective: 12/01/2020
In summary - author hyperlinks to a study, quotes it, tells us where the quote is to be found, AND there is no such quote.
We're being punked dudes.